FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Johan Mouton

Research Profile

Procedures

Chemicals & Drugs

Concepts & Ideas

Disorders

Living Beings

Physiology

Bacterial Drug Resistance

Co-author Network

Publications

TOP 3
Anouk E Muller; Nieko Punt; Anne H Schmitt-Hoffmann; Johan W Mouton
Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study.
Seyedmojtaba Seyedmousavi; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis.
Anouk E Muller; Nieko Punt; Johan W Mouton
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Johan Mouton (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Anouk E Muller; Nieko Punt; Anne H Schmitt-Hoffmann; Johan W Mouton
Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study.
Antimicrobial agents and chemotherapy 2013;57(5):2047-53.
2013: Seyedmojtaba Seyedmousavi; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis.
Antimicrobial agents and chemotherapy 2013;57(4):1866-71.
2013: Anouk E Muller; Nieko Punt; Johan W Mouton
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia.
The Journal of antimicrobial chemotherapy 2013;68(4):900-6.
2013: Seyedmojtaba Seyedmousavi; Willem J G Melchers; Joseph Meletiadis; Johan W Mouton; Antonius J M M Rijs; Paul E Verweij
In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.
Antimicrobial agents and chemotherapy 2013;57(2):796-803.
2013: Seyedmojtaba Seyedmousavi; Paul E Verweij; Roger J M Brüggemann; Willem J G Melchers; Antonius J M M Rijs; Johan W Mouton
Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.
The Journal of antimicrobial chemotherapy 2013;68(2):385-93.
2013: W H F Goessens; Martina Kinzig; Johan W Mouton; Fritz Sörgel; Marian T ten Kate; Irma A J M Bakker-Woudenberg
The therapeutic effect of tigecycline, unlike that of Ceftazidime, is not influenced by whether the Klebsiella pneumoniae strain produces extended-spectrum β-lactamases in experimental pneumonia in rats.
Antimicrobial agents and chemotherapy 2013;57(1):643-6.
2013: Seyedmojtaba Seyedmousavi; Paul E Verweij; Roger J M Brüggemann; Willem J G Melchers; Johan W Mouton
Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.
Antimicrobial agents and chemotherapy 2013;57(1):303-8.
2012: Jakko van Ingen; Rob E Aarnoutse; Martin J Boeree; Eric F Egelund; Leonid B Heifets; Adrah Levin; Johan W Mouton; Charles A Peloquin; Sarah E Totten; Charles L Daley
The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.
American journal of respiratory and critical care medicine 2012;186(6):559-65.
2012: Jakko van Ingen; Dick Van Soolingen; Martin J Boeree; Johan W Mouton
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2012;15(3):149-61.
2011: Ursula Theuretzbacher; Johan W Mouton
Update on antibacterial and antifungal drugs - can we master the resistance crisis?
Current opinion in pharmacology 2011;11(5):429-32.
2011: Seyedmojtaba Seyedmousavi; Paul E Verweij; Willem J G Melchers; Johan W Mouton
Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR.
Current opinion in pharmacology 2011;11(5):486-93.
2011: Markus A Zeitlinger; David Andes; Otto Cars; William A Craig; Hartmut Derendorf; Johan W Mouton; Ursula Theuretzbacher
Protein binding: do we ever learn?
Antimicrobial agents and chemotherapy 2011;55(7):3067-74.
2011: Saskia Kuipers; Willem J G Melchers; Johan W Mouton; Roger J M Brüggemann; Ruud G L de Sévaux; John P F A Heesakkers; Paul E Verweij
Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole.
Antimicrobial agents and chemotherapy 2011;55(7):3564-6.
2011: Johan W Mouton
Relationship between pharmacodynamic indices and killing patterns in vitro.
Future microbiology 2011;6(6):613-6.
2011: Johan W Mouton; Paul G Ambrose; Rafael Canton; George L Drusano; Stephan Harbarth; Alasdair MacGowan; Ursula Theuretzbacher; John Turnidge
Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2011;14(2):107-17.
2011: Lieven B van der Velden; Fidel J Vos; Johan W Mouton; P D J Sturm
Clinical impact of preincubation of blood cultures at 37°C.
Journal of clinical microbiology 2011;49(1):275-80.
2010: Eleftheria Mavridou; Roger J M Bruggemann; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.
Antimicrobial agents and chemotherapy 2010;54(11):4758-64.
2010: C C Van Leer Buter; Johan W Mouton; Corné Klaassen; C M A Handgraaf; S Sunnen; W J G Melchers; P D J Sturm
Prevalence and molecular mechanism of macrolide resistance in beta-haemolytic streptococci in The Netherlands.
International journal of antimicrobial agents 2010;35(6):590-2.
2010: Eleftheria Mavridou; Roger J M Brüggemann; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
Antimicrobial agents and chemotherapy 2010;54(2):860-5.
2009: Johan W Mouton; D T A Te Dorsthorst; J F G M Meis; Paul E Verweij
Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2009;47(8):802-7.
2008: Paul E Verweij; D T A Te Dorsthorst; Willem H P Janssen; Jacques Meis; Johan W Mouton
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
Antimicrobial agents and chemotherapy 2008;52(12):4483-5.
2008: J Buijs; A S M Dofferhoff; Johan W Mouton; J H T Wagenvoort; J W M van der Meer
Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2008;14(4):344-9.
2008: Johan W Mouton; Ursula Theuretzbacher; William A Craig; Paul Tulkens; Hartmut Derendorf; Otto Cars
Tissue concentrations: do we ever learn?
The Journal of antimicrobial chemotherapy 2008;61(2):235-7.
2007: Johan W Mouton; Alexander Vinks
Continuous infusion of beta-lactams.
Current opinion in critical care 2007;13(5):598-606.
2007: Lorna E T Stearne; W H F Goessens; Johan W Mouton; Inge C Gyssens
Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infection.
Antimicrobial agents and chemotherapy 2007;51(10):3605-11.
2007: Johan W Mouton; Nieko Punt; Alexander Vinks
Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.
Antimicrobial agents and chemotherapy 2007;51(9):3449-51.
2007: Jacqueline Buijs; A S M Dofferhoff; Johan W Mouton; Jos W M van der Meer
Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.
The Journal of antimicrobial chemotherapy 2007;59(5):926-33.
2007: W H F Goessens; Johan W Mouton; Marian T ten Kate; A J Bijl; Alewijn Ott; Irma A J M Bakker-Woudenberg
Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection.
The Journal of antimicrobial chemotherapy 2007;59(3):507-16.
2006: J Buijs; A S M Dofferhoff; Johan W Mouton; J W M van der Meer
Pathophysiology of in-vitro induced filaments, spheroplasts and rod-shaped bacteria in neutropenic mice.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12(11):1105-11.
2006: Irma A J M Bakker-Woudenberg; Marian T ten Kate; W H F Goessens; Johan W Mouton
Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection.
Antimicrobial agents and chemotherapy 2006;50(9):2919-25.
2005: D T A Te Dorsthorst; Paul E Verweij; Jacques Meis; Johan W Mouton
Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.
Antimicrobial agents and chemotherapy 2005;49(10):4220-6.
2005: Hanneke A De Valk; Jacques Meis; Ilse M Curfs; Konrad Muehlethaler; Johan W Mouton; Corné Klaassen
Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates.
Journal of clinical microbiology 2005;43(8):4112-20.
2005: D T A Te Dorsthorst; Paul E Verweij; Jacques Meis; Johan W Mouton
Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates.
Antimicrobial agents and chemotherapy 2005;49(8):3341-6.
2005: Johan W Mouton; Nieko Punt; Alexander Vinks
A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
Clinical therapeutics 2005;27(6):762-72.
2005: Johan W Mouton; Nico Jacobs; Harm A W M Tiddens; Alphons Horrevorts
Pharmacodynamics of tobramycin in patients with cystic fibrosis.
Diagnostic microbiology and infectious disease 2005;52(2):123-7.
2005: Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
The Journal of antimicrobial chemotherapy 2005;55(5):601-7.
2005: Corné Klaassen; Johan W Mouton
Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E).
Antimicrobial agents and chemotherapy 2005;49(4):1271-8.
2005: Matthijs de Hoog; Johan W Mouton; John N van den Anker
New dosing strategies for antibacterial agents in the neonate.
Seminars in fetal & neonatal medicine 2005;10(2):185-94.
2005: Debby M Klomberg; Hanneke A De Valk; Johan W Mouton; Corné Klaassen
Rapid and reliable real-time PCR assay for detection of the macrolide efflux gene and subsequent discrimination between its distinct subclasses mef(A) and mef(E).
Journal of microbiological methods 2005;60(2):269-73.
2005: Johan W Mouton; Alexander Vinks
Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.
Clinical pharmacokinetics 2005;44(2):201-10.
2004: D T A Te Dorsthorst; Johan W Mouton; C J P van den Beukel; H A L van der Lee; Jacques Meis; Paul E Verweij
Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.
Antimicrobial agents and chemotherapy 2004;48(8):3147-50.
2004: SE Buijk; Inge C Gyssens; Johan W Mouton; Herold J Metselaar; Theo H N Groenland; Henri A Verbrugh; Hajo A Bruining
Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients.
The Journal of antimicrobial chemotherapy 2004;54(1):199-205.
2004: D T A Te Dorsthorst; Paul E Verweij; Jacques Meis; Nieko Punt; Johan W Mouton
In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models.
Antimicrobial agents and chemotherapy 2004;48(6):2007-13.
2004: Johan W Mouton; Anne Schmitt-Hoffmann; Stuart Shapiro; Norman Nashed; Nieko Punt
Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.
Antimicrobial agents and chemotherapy 2004;48(5):1713-8.
2004: Lorna E T Stearne; Doret van Boxtel; Nicole Lemmens; W H F Goessens; Johan W Mouton; Inge C Gyssens
Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.
Antimicrobial agents and chemotherapy 2004;48(5):1688-98.
2004: Matthijs de Hoog; Johan W Mouton; John N van den Anker
Vancomycin: pharmacokinetics and administration regimens in neonates.
Clinical pharmacokinetics 2004;43(7):417-40.
2003: Johan W Mouton
Impact of pharmacodynamics on breakpoint selection for susceptibility testing.
Infectious disease clinics of North America 2003;17(3):579-98.
2002: Johan W Mouton; MF Peeters; J H van Rijssort-Vos; Roel P Verkooyen
Tubal factor pathology caused by Chlamydia trachomatis: the role of serology.
International journal of STD & AIDS 2002;13 Suppl 2():26-9.
2002: Roel P Verkooyen; MF Peeters; J H van Rijsoort-Vos; Willem I van der Meijden; Johan W Mouton
Sensitivity and specificity of three new commercially available Chlamydia trachomatis tests.
International journal of STD & AIDS 2002;13 Suppl 2():23-5.
2002: Lorna E T Stearne; Steven L Buijk; Johan W Mouton; Inge C Gyssens
Effect of a single percutaneous abscess drainage puncture and imipenem therapy, alone or in combination, in treatment of mixed-infection abscesses in mice.
Antimicrobial agents and chemotherapy 2002;46(12):3712-8.
2002: Erik Honig; Johan W Mouton; Willem I van der Meijden
The epidemiology of vaginal colonisation with group B streptococci in a sexually transmitted disease clinic.
European journal of obstetrics, gynecology, and reproductive biology 2002;105(2):177-80.
2002: D T A Te Dorsthorst; Paul E Verweij; Joseph Meletiadis; M Bergervoet; Nieko Punt; Jacques Meis; Johan W Mouton
In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach.
Antimicrobial agents and chemotherapy 2002;46(9):2982-9.
2002: Irma A J M Bakker-Woudenberg; Marian T ten Kate; Luke Guo; Peter Working; Johan W Mouton
Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.
Antimicrobial agents and chemotherapy 2002;46(8):2575-81.
2002: SE Buijk; Johan W Mouton; Inge C Gyssens; Henri A Verbrugh; Hajo A Bruining
Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
Intensive care medicine 2002;28(7):936-42.
2002: Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs.
International journal of antimicrobial agents 2002;19(4):355-8.
2002: Johan W Mouton
Breakpoints: current practice and future perspectives.
International journal of antimicrobial agents 2002;19(4):323-31.
2002: D T A Te Dorsthorst; Paul E Verweij; Jacques Meis; Nieko Punt; Johan W Mouton
Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates.
Antimicrobial agents and chemotherapy 2002;46(3):702-7.
2002: Steven L Buijk; Inge C Gyssens; Johan W Mouton; A Van Vliet; Henri A Verbrugh; Hajo A Bruining
Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections.
The Journal of antimicrobial chemotherapy 2002;49(1):121-8.
2001: Irma A J M Bakker-Woudenberg; Marian T ten Kate; Luke Guo; Peter Working; Johan W Mouton
Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.
Antimicrobial agents and chemotherapy 2001;45(5):1487-92.
2001: Lorna E T Stearne; Inge C Gyssens; W H F Goessens; Johan W Mouton; Wim J G Oyen; Jos W M van der Meer; Henri A Verbrugh
In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Antimicrobial agents and chemotherapy 2001;45(5):1394-401.
2001: Johan W Mouton; Nieko Punt
Use of the t > MIC to choose between different dosing regimens of beta-lactam antibiotics.
The Journal of antimicrobial chemotherapy 2001;47(4):500-1.
2001: Steven L Buijk; Inge C Gyssens; Johan W Mouton; Henri A Verbrugh; D J Touw; Hajo A Bruining
Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function.
Intensive care medicine 2001;27(1):115-21.
1999: A van't Veen; Diederik Gommers; Serge J C Verbrugge; P Wollmer; Johan W Mouton; Peter P M Kooij; Burkhard Lachmann
Lung clearance of intratracheally instilled 99mTc-tobramycin using pulmonary surfactant as vehicle.
British journal of pharmacology 1999;126(5):1091-6.
1999: Erik Honig; Johan W Mouton; Willem I van der Meijden
Can group B streptococci cause symptomatic vaginitis?
Infectious diseases in obstetrics and gynecology 1999;7(4):206-9.
1998: Siem de Marie; MF VandenBergh; Steven L Buijk; Hajo A Bruining; A van Vliet; Jan A J W Kluytmans; Johan W Mouton
Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections.
Intensive care medicine 1998;24(4):343-6.
1998: Jan G Den Hollander; Kurt Fuursted; Henri A Verbrugh; Johan W Mouton
Duration and clinical relevance of postantibiotic effect in relation to the dosing interval.
Antimicrobial agents and chemotherapy 1998;42(4):749-54.
1998: Jan G Den Hollander; Johan W Mouton; Henri A Verbrugh
Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.
Antimicrobial agents and chemotherapy 1998;42(4):744-8.
1998: Jan G Den Hollander; Jenny Dahl Knudsen; Johan W Mouton; Kurt Fuursted; Niels Frimodt-Møller; Henri A Verbrugh; Frank Espersen
Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo.
Antimicrobial agents and chemotherapy 1998;42(2):377-82.
1997: W H F Goessens; Johan W Mouton; Willem I van der Meijden; S Deelen; TH van Rijsoort-Vos; N Lemmens-den Toom; Henri A Verbrugh; Roel P Verkooyen
Comparison of three commercially available amplification assays, AMP CT, LCx, and COBAS AMPLICOR, for detection of Chlamydia trachomatis in first-void urine.
Journal of clinical microbiology 1997;35(10):2628-33.
1997: Johan W Mouton; Roel P Verkooyen; Willem I van der Meijden; TH van Rijsoort-Vos; W H F Goessens; Jan A J W Kluytmans; S D Deelen; Ad Luijendijk; Henri A Verbrugh
Detection of Chlamydia trachomatis in male and female urine specimens by using the amplified Chlamydia trachomatis test.
Journal of clinical microbiology 1997;35(6):1369-72.
1997: Johan W Mouton; Hubert P Endtz; Jan G Den Hollander; Nicole van den Braak; Henri A Verbrugh
In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis.
The Journal of antimicrobial chemotherapy 1997;39 Suppl A():75-80.
1997: Hubert P Endtz; Johan W Mouton; Jan G Den Hollander; Nicole van den Braak; Henri A Verbrugh
Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
Antimicrobial agents and chemotherapy 1997;41(5):1146-9.
1997: Johan W Mouton; A A Vinks; Nieko Punt
Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.
Antimicrobial agents and chemotherapy 1997;41(4):733-8.